Skip to main content
. Author manuscript; available in PMC: 2015 Jun 1.
Published in final edited form as: Pediatr Infect Dis J. 2014 Jun;33(6):617–622. doi: 10.1097/INF.0000000000000222

Figure 2.

Figure 2

Program Year effect on 6 and 12 month viral suppression rates stratified by abacavir (ABC) and stavudine (d4T) for children on ritonavir-boosted lopinavir (LPV/r – panel A) and efavirenz (EFV – panel B) respectively.